Pharming Grp Nv Leid (PHGUF) 0.3500 $PHGUF Phar
Post# of 273239
Posted On: 04/12/2015 8:42:25 AM
Pharming Grp Nv Leid (PHGUF) 0.3500 $PHGUF
Pharming nominates two new members to board of supervisory directors
M2 - Fri Mar 20, 5:49AM CDT
Medical company Pharming Group NV (Amsterdam
HARM.AS) revealed on Thursday that Paul Jai Sekhri and Jan Hendrik Egberts have been nominated to its board of supervisory directors.
Pharming Nominates Paul Sekhri and Jan Egberts as Members of its Board of Supervisory Directors
PR Newswire Europe - Thu Mar 19, 1:01AM CDT
LEIDEN, The Netherlands, March 19, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming Group: Amid Current Bidding War For Salix, Everything Seems Fine For Ruconest And U.S. Sales
Logribel Biostocks - at Seeking Alpha - Fri Mar 13, 9:49AM CDT
ENDP: 94.46 (+0.78), VRX: 207.50 (+1.78), SHPG: 248.77 (-5.55), SLXP: 172.96 (+0.15)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 207.50 (+1.78), SLXP: 172.96 (+0.15), ICPT: 279.25 (+7.48), SPPI: 6.00 (+0.08), EXAS: 22.76 (-0.10)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 425.65 (-0.98), BMRN: 122.20 (+0.12), CVM: 0.99 (-0.01), MDGN: 8.69 (+0.65), PFE: 35.44 (+0.41), SGMO: 15.41 (+0.29), RPRX: 9.26 (+0.56), MNKD: 5.25 (unch), CELG: 117.07 (+1.49), SGEN: 37.09 (+0.88), TEVA: 66.37 (-0.77), ARIA: 8.46 (+0.10), SNY: 52.35 (+0.48), REGN: 461.39 (+6.35)
Pharming Group: A Potential Genzyme In The Making
Logribel Biostocks - at Seeking Alpha - Wed Feb 18, 1:29PM CST
BAX: 70.57 (+0.42), SHPG: 248.77 (-5.55), SLXP: 172.96 (+0.15), SNY: 52.35 (+0.48), DYAX: 29.20 (+0.21)
Pharming hires Dr Perry Calias as CSO
M2 - Wed Feb 18, 6:19AM CST
Medical products company Pharming Group NV (Amsterdam HARM.AS) disclosed on Tuesday the election of Dr Perry Calias as the chief scientific officer (CSO).
Pharming Appoints Dr. Perry Calias as Chief Scientific Officer
PR Newswire Europe - Wed Feb 18, 12:01AM CST
LEIDEN, The Netherlands, February 18, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pancreatitis Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Wed Jan 21, 4:31AM CST
The report "Pancreatitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Pancreatitis. Pancreatitis simply means inflammation of the pancreas. Pancreatic damage happens when the digestive enzymes are activated before they are released into the small intestine and begin attacking the pancreas. Acute pancreatitis is a sudden inflammation that lasts for a short time. Chronic pancreatitis is long-lasting inflammation of the pancreas. It most often happens after an episode of acute pancreatitis. The most common symptoms of pancreatitis are severe upper abdominal or left upper quadrant burning pain radiating to the back, nausea and vomiting that is worsened with eating. Complete Report is Available @ http://www.rnrmarketresearch.com/pancreatitis...eport.html .
DVAX: 22.61 (+0.19), GSK: 48.23 (+0.51)
Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest(R) for Prophylaxis of Hereditary Angioedema
Business Wire - Thu Jan 08, 9:33AM CST
Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 clinical study of Ruconest(R), (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, for prophylaxis in patients with hereditary angioedema (HAE).
SLXP: 172.96 (+0.15)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 24.58 (+0.44)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming and Salix partnership unveils RUCONEST for treating acute angioedema attacks in patients with HAE in the US
M2 - Mon Nov 03, 3:45AM CST
Pharming Group NV (Amsterdam HARM.AS) and Salix Pharmaceuticals (NasdaqGS:SLXP) on Monday jointly announced the introduction of RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
SLXP: 172.96 (+0.15)
Pharming and Swedish Orphan Biovitrum amends and extends Ruconest distribution agreement in Austria, Germany and Netherlands
M2 - Tue Oct 14, 6:10AM CDT
Biotech company Pharming Group NV (Amsterdam HARM.AS) reported on Monday the amendment and extension of the Ruconest distribution agreement with Swedish Orphan Biovitrum AB (publ) (SS:SOBI).
Kidney Transplantation Therapeutic Pipeline Review, H2 2014 - 29 Drug Profiles From 18 Companies
M2 - Tue Sep 09, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqfkc/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Grifols, S.A. - Novartis AG - Astellas Pharma Inc. - Shire Plc - Veloxis Pharmaceuticals A/S - La Jolla Pharmaceutical Company - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Bio-inRen Drug Profiles - tacrolimus ER - voclosporin - eculizumab - ASKP-1240 - belimumab - foralumab - cardiotrophin-1 - C1 esterase inhibitor (human) - BB-3 - QPI-1002 - TOL-101 - OPN-305 - IgG-Degrading Enzyme of Streptococcus pyogenes - FCR-001 - Immucellgram - C1 esterase inhibitor (human) - CFZ-533 - VT-111a - VT-214 - C1 esterase inhibitor (recombinant) - LJPC-101 - AS-2521780 - FFP-106 - ETR-002 - Cell Therapy for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - BRN-1889 - albumin (human) For more information visit http://www.researchandmarkets.com/research/2mqfkc/kidney
SHPG: 248.77 (-5.55), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
Pancreatitis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kdxqj/pancreatitis) has announced the addition of the "Pancreatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pancreatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Pharming Group N.V. - D-Pharm Ltd. - AIM Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/8k...ncreatitis
GSK: 48.23 (+0.51)
Pharming nominates two new members to board of supervisory directors
M2 - Fri Mar 20, 5:49AM CDT
Medical company Pharming Group NV (Amsterdam
HARM.AS) revealed on Thursday that Paul Jai Sekhri and Jan Hendrik Egberts have been nominated to its board of supervisory directors. Pharming Nominates Paul Sekhri and Jan Egberts as Members of its Board of Supervisory Directors
PR Newswire Europe - Thu Mar 19, 1:01AM CDT
LEIDEN, The Netherlands, March 19, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming Group: Amid Current Bidding War For Salix, Everything Seems Fine For Ruconest And U.S. Sales
Logribel Biostocks - at Seeking Alpha - Fri Mar 13, 9:49AM CDT
ENDP: 94.46 (+0.78), VRX: 207.50 (+1.78), SHPG: 248.77 (-5.55), SLXP: 172.96 (+0.15)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 207.50 (+1.78), SLXP: 172.96 (+0.15), ICPT: 279.25 (+7.48), SPPI: 6.00 (+0.08), EXAS: 22.76 (-0.10)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 425.65 (-0.98), BMRN: 122.20 (+0.12), CVM: 0.99 (-0.01), MDGN: 8.69 (+0.65), PFE: 35.44 (+0.41), SGMO: 15.41 (+0.29), RPRX: 9.26 (+0.56), MNKD: 5.25 (unch), CELG: 117.07 (+1.49), SGEN: 37.09 (+0.88), TEVA: 66.37 (-0.77), ARIA: 8.46 (+0.10), SNY: 52.35 (+0.48), REGN: 461.39 (+6.35)
Pharming Group: A Potential Genzyme In The Making
Logribel Biostocks - at Seeking Alpha - Wed Feb 18, 1:29PM CST
BAX: 70.57 (+0.42), SHPG: 248.77 (-5.55), SLXP: 172.96 (+0.15), SNY: 52.35 (+0.48), DYAX: 29.20 (+0.21)
Pharming hires Dr Perry Calias as CSO
M2 - Wed Feb 18, 6:19AM CST
Medical products company Pharming Group NV (Amsterdam
HARM.AS) disclosed on Tuesday the election of Dr Perry Calias as the chief scientific officer (CSO). Pharming Appoints Dr. Perry Calias as Chief Scientific Officer
PR Newswire Europe - Wed Feb 18, 12:01AM CST
LEIDEN, The Netherlands, February 18, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pancreatitis Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Wed Jan 21, 4:31AM CST
The report "Pancreatitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Pancreatitis. Pancreatitis simply means inflammation of the pancreas. Pancreatic damage happens when the digestive enzymes are activated before they are released into the small intestine and begin attacking the pancreas. Acute pancreatitis is a sudden inflammation that lasts for a short time. Chronic pancreatitis is long-lasting inflammation of the pancreas. It most often happens after an episode of acute pancreatitis. The most common symptoms of pancreatitis are severe upper abdominal or left upper quadrant burning pain radiating to the back, nausea and vomiting that is worsened with eating. Complete Report is Available @ http://www.rnrmarketresearch.com/pancreatitis...eport.html .
DVAX: 22.61 (+0.19), GSK: 48.23 (+0.51)
Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest(R) for Prophylaxis of Hereditary Angioedema
Business Wire - Thu Jan 08, 9:33AM CST
Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 clinical study of Ruconest(R), (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, for prophylaxis in patients with hereditary angioedema (HAE).
SLXP: 172.96 (+0.15)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 24.58 (+0.44)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming and Salix partnership unveils RUCONEST for treating acute angioedema attacks in patients with HAE in the US
M2 - Mon Nov 03, 3:45AM CST
Pharming Group NV (Amsterdam
HARM.AS) and Salix Pharmaceuticals (NasdaqGS:SLXP) on Monday jointly announced the introduction of RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). SLXP: 172.96 (+0.15)
Pharming and Swedish Orphan Biovitrum amends and extends Ruconest distribution agreement in Austria, Germany and Netherlands
M2 - Tue Oct 14, 6:10AM CDT
Biotech company Pharming Group NV (Amsterdam
HARM.AS) reported on Monday the amendment and extension of the Ruconest distribution agreement with Swedish Orphan Biovitrum AB (publ) (SS:SOBI). Kidney Transplantation Therapeutic Pipeline Review, H2 2014 - 29 Drug Profiles From 18 Companies
M2 - Tue Sep 09, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqfkc/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Grifols, S.A. - Novartis AG - Astellas Pharma Inc. - Shire Plc - Veloxis Pharmaceuticals A/S - La Jolla Pharmaceutical Company - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Bio-inRen Drug Profiles - tacrolimus ER - voclosporin - eculizumab - ASKP-1240 - belimumab - foralumab - cardiotrophin-1 - C1 esterase inhibitor (human) - BB-3 - QPI-1002 - TOL-101 - OPN-305 - IgG-Degrading Enzyme of Streptococcus pyogenes - FCR-001 - Immucellgram - C1 esterase inhibitor (human) - CFZ-533 - VT-111a - VT-214 - C1 esterase inhibitor (recombinant) - LJPC-101 - AS-2521780 - FFP-106 - ETR-002 - Cell Therapy for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - BRN-1889 - albumin (human) For more information visit http://www.researchandmarkets.com/research/2mqfkc/kidney
SHPG: 248.77 (-5.55), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
Pancreatitis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kdxqj/pancreatitis) has announced the addition of the "Pancreatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pancreatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Pharming Group N.V. - D-Pharm Ltd. - AIM Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/8k...ncreatitis
GSK: 48.23 (+0.51)
(0)
(0)